Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single group trial evaluating one cycle of adjuvant bleomycin, etoposide, platinum (BEP) chemotherapy in high risk, stage one non-seminomatous germ cell tumours of the testis (NSGCTT).

Next Previous
Trial Profile

A single group trial evaluating one cycle of adjuvant bleomycin, etoposide, platinum (BEP) chemotherapy in high risk, stage one non-seminomatous germ cell tumours of the testis (NSGCTT).

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bleomycin; Cisplatin; Etoposide
  • Indications Testicular cancer
  • Focus Therapeutic Use
  • Acronyms 111Trial; BEP111

Most Recent Events

  • 04 May 2020 Biomarkers information updated
  • 25 Dec 2013 Accrual to date is 83% according to United Kingdom Clinical Research Network record.
  • 20 Oct 2013 Accrual to date is 78% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top